版本:
中国

BRIEF-Janssen Pharmaceuticals says evidence shows oral invokana 300 mg demonstrates comparable A1C reduction

May 5 Johnson & Johnson

* Janssen Pharmaceuticals - real-world evidence shows oral invokana 300 mg demonstrates comparable A1C reduction and control to injectable GLP-1 receptor agonists

* Janssen Pharmaceuticals Inc - patients on invokana were also less likely to discontinue their medication or be prescribed new antihyperglycemic agent Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐